サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654724

肺がん診断の世界市場：2025年～2033年

Global Lung Cancer Diagnostics Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺がん診断の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺がん診断の世界市場は、2024年に49億4,000万米ドルに達し、2033年までには84億4,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは6.18%で成長すると予測されています。

肺がん診断は、肺がんの早期発見、正確な診断、効果的な治療のために極めて重要です。肺がんを早期に発見することは、最善の治療方針を決定し、生存率を向上させるために不可欠です。CTスキャン、X線、PETスキャンなどの画像診断技術や、バイオマーカー検査、遺伝子解析など、さまざまな診断方法が用いられます。

より新しく非侵襲的な技術であるリキッドバイオプシーも、遺伝子変異やがんの特異的な特徴を特定するために人気を集めています。これらの進歩により、標的療法や免疫療法など、より個別化された治療計画を立てることが可能になり、患者の予後改善に有望な結果をもたらしています。

市場力学：

促進要因と抑制要因

肺がん罹患率の上昇

肺がん罹患率の上昇は、肺がん診断市場の成長を促進する重要な要因です。罹患者数が世界中で増加し続けているため、効果的な早期発見方法の必要性が高まっています。肺がんは、喫煙、大気汚染、その他の環境的影響などの要因によるところが大きく、依然として最も死亡率の高い一般的ながんの一つです。

毎年多くの人が診断されるようになり、より早期に、より治療可能な段階で病気を発見するための高度な診断ツールの需要は著しく高まっています。例えば、米国がん協会によると、2025年には約22万6,650人の肺がん患者が新たに報告されると推定されています。肺がんの統計には通常、小細胞肺がん（SCLC）と非小細胞肺がん（NSCLC）の両方が含まれます。一般に、SCLCは肺がん症例全体の約13％を占め、NSCLCは約87％を占めます。

肺がん症例数の増加に伴い、ヘルスケアプロバイダーも患者も生存率を向上させるために、より正確で効率的、かつ利用しやすい診断方法を求めています。より良い転帰を得るためには早期発見が不可欠であり、低線量CTスキャンやバイオマーカー検査のようなスクリーニングツールの必要性が高まっています。したがって、肺がん患者数の増加が肺がん診断市場の主要な促進要因となっています。

診断検査コストの高さ

診断検査のコストが高いことは、特に低・中所得地域における先進技術へのアクセスを制限することにより、肺がん診断市場の成長にとって大きな課題となっています。リキッドバイオプシー、ゲノム検査、PETスキャンなどの高価な診断方法は、多くの患者にとって経済的に手が届かないことが多く、その結果、診断が遅れたり、精度が低く、より安価な代替医療に頼ることになります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 肺がん発症率の上昇
    • 抑制要因
      • 治療費の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 がんタイプ別

  • 非小細胞肺がん
  • 小細胞肺がん

第7章 診断テストタイプ別

  • 生検
  • 画像検査
  • 分子検査
  • その他

第8章 製品タイプ別

  • 機器
  • 消耗品

第9章 エンドユーザー別

  • 病院
  • 診断センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Biodesix
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • DSS Imagetec
  • Abbott
  • Guardant Health
  • Intuitive Surgical
  • bioAffinity Technologies, Inc.
  • Optellum Ltd
  • F. Hoffmann-La Roche Ltd.
  • 各市場参加者に対しても同様のデータが提供されます。

第13章 付録

目次
Product Code: PH7811

The global lung cancer diagnostics market reached US$ 4.94 billion in 2024 and is expected to reach US$ 8.44 billion by 2033, growing at a CAGR of 6.18% during the forecast period 2025-2033.

Lung cancer diagnostics are crucial for early detection, accurate diagnosis, and effective treatment of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Detecting lung cancer early is vital for determining the best course of treatment and improving survival rates. A variety of diagnostic methods are used, including imaging techniques like CT scans, X-rays, and PET scans, as well as biomarker testing and genetic analysis.

Liquid biopsy, a newer and non-invasive technology, is also gaining popularity for identifying genetic mutations and specific characteristics of the cancer. These advancements have made it possible to create more personalized treatment plans, such as targeted therapies or immunotherapies, which are showing promising results in improving patient outcomes.

Market Dynamics: Drivers & Restraints

Rising incidence of lung cancer cases

The rising incidence of lung cancer is a key factor driving the growth of the lung cancer diagnostics market. As the number of cases continues to increase worldwide, there's a greater need for effective and early detection methods. Lung cancer remains one of the deadliest and most common cancers, largely due to factors like smoking, air pollution, and other environmental influences.

With more people being diagnosed each year, the demand for advanced diagnostic tools to catch the disease at an earlier, more treatable stage has grown significantly. For instance, according to the American Cancer Society, it is estimated that about 226,650 new cases of lung cancer cases are expected to report in 2025. Lung cancer statistics typically encompass both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Generally, SCLC accounts for about 13% of all lung cancer cases, while NSCLC makes up approximately 87%.

As the number of lung cancer cases rises, both healthcare providers and patients are looking for more accurate, efficient, and accessible diagnostic options to improve survival rates. Early detection is essential for better outcomes, and there's an increasing need for screening tools like low-dose CT scans and biomarker testing. Thus, the growing number of lung cancer cases is a major driver for the lung cancer diagnostics market.

High Costs of Diagnostic Tests

The high cost of diagnostic tests poses a significant challenge to the growth of the lung cancer diagnostics market by restricting access to advanced technologies, especially in low- and middle-income regions. Expensive diagnostic methods, such as liquid biopsies, genomic testing, and PET scans, are often financially inaccessible to many patients, resulting in delayed diagnoses or reliance on less precise, more affordable alternatives.

Segment Analysis

The global lung cancer diagnostics market is segmented based on cancer type, diagnostic test type, product type, end-user, and region.

Treatment:

Biopsy segment is expected to dominate the global lung cancer diagnostics market share

The biopsy segment is expected to lead the lung cancer diagnostics market because it plays a vital role in accurately diagnosing lung cancer. Methods like needle biopsies, bronchoscopic biopsies, and surgical biopsies are essential for confirming the presence of cancer cells and determining the type and stage of the disease. Different biopsy tests are introduced by the companies to enhance the accuracy of the diagnostic procedures. For instance, in October 2023, Delfi Diagnostics introduced its first liquid biopsy test, fulfilling the company's long-standing goal of providing a blood-based screening tool for lung cancer. The Firstlook Lung test aims to offer a more accessible and convenient detection method, reaching a broader population compared to current standards.

Recent advancements in minimally invasive techniques, such as CT-guided needle biopsies and EBUS-guided biopsies, have made it easier to collect tissue samples with fewer risks, which has led to wider adoption in clinical practice. Companies are forming partnerships to widen the usage pof the existing tests and products. For instance, in January 2023, Agilent and Quest Diagnostics have partnered to broaden access to the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This FDA-approved, single-site premarket test serves as a companion diagnostic (CDx) to identify patients with advanced non-small cell lung cancer (NSCLC) who may benefit from treatment with adagrasib (brand name Krazati).

As precision medicine continues to gain importance, biopsies are key for genomic profiling and identifying biomarkers, which are crucial for selecting the most effective targeted therapies and immunotherapies. This ability to support personalized treatment is a major factor driving the dominance of the biopsy segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global lung cancer diagnostics market share

North America is expected to maintain a dominant position in the global lung cancer diagnostics market, driven by its advanced healthcare infrastructure and high lung cancer incidence. The region's access to cutting-edge diagnostic technologies, such as advanced imaging systems, liquid biopsies, and genomic testing, enables early and accurate detection of lung cancer, which is crucial for improving patient outcomes.

Growing awareness about the importance of early lung cancer screening, along with a rising emphasis on precision medicine, has fuelled the demand for effective and personalized diagnostic solutions. Moreover, the significant investments in healthcare research for diagnostic procedures, ensure that patients have greater access to the latest diagnostic tools. For instance, in October 2023, DELFI Diagnostics, Inc., a company focused on accessible blood-based tests to improve cancer detection, has announced the initial commercial launch of FirstLook Lung. This blood test provides a convenient, accurate, and personalized result by assessing the likelihood of detecting lung cancer through low-dose CT (LDCT), boasting an impressive negative predictive value (NPV) of 99.7%. These factors hold the region in the dominant position in the lung cancer diagnostics market.

Competitive Landscape

The major global players in the lung cancer diagnostics market include Quest Diagnostics Incorporated, Biodesix, Lepu Medical Technology (Beijing)Co., Ltd., DSS Imagetec, Abbott, Guardant Health, Intuitive Surgical, bioAffinity Technologies, Inc., Optellum Ltd and F. Hoffmann-La Roche Ltd. among others.

Key Developments

  • In January 2025, Monitor Corporation has begun selling its lung cancer diagnosis software in Japan through a partnership with Doctor-NET, a Japanese digital healthcare provider.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Lung Cancer Diagnostics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Diagnostic Test Type
  • 3.3. Snippet by Product Type
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of lung cancer cases
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Cancer Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 6.1.2. Market Attractiveness Index, By Cancer Type
  • 6.2. Non-small Cell Lung Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Small Cell Lung Cancer

7. By Diagnostic Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
  • 7.2. Biopsies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Imaging Tests
  • 7.4. Molecular Testing
  • 7.5. Others

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.1.2. Market Attractiveness Index, By Product Type
  • 8.2. Instruments*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Consumables

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Biodesix
  • 12.3. Lepu Medical Technology (Beijing)Co., Ltd.
  • 12.4. DSS Imagetec
  • 12.5. Abbott
  • 12.6. Guardant Health
  • 12.7. Intuitive Surgical
  • 12.8. bioAffinity Technologies, Inc.
  • 12.9. Optellum Ltd
  • 12.10. F. Hoffmann-La Roche Ltd.
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us